# US 7,745,128 B2 · Ras mutation and compositions and methods related thereto > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,745,128 B2 - Document ID: US7745128B2 - Status: Granted - Kind: B2 - Application number: 11/684,290 - Filed: 2007-03-09 - Published: 2007-09-27 - Granted: 2010-06-29 - Earliest claimed: 2006-03-27 - Assignees: GlobeImmune, Inc. - Inventors: Zhimin Guo; Yingnian Lu; Donald Bellgrau; Alex Franzusoff - Web page: https://patentgrep.com/patent/US7745128B2 ## CPC - C07K 14/82: Translation products from oncogenes - A61K 39/001162: {Kinases, e.g. Raf or Src} - A61P 35/00: Antineoplastic agents - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/575: for cancer - A61K 2039/5156: {expressing foreign proteins} - A61K 2039/523: {expressing foreign proteins} - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/178: miRNA, siRNA or ncRNA - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - Y10T 436/143333: Saccharide [e.g., DNA, etc.] - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations. ## Claims ### Claim 1 A method for detecting mutated Ras in a test sample, comprising: a. obtaining a test sample from a patient; and b. detecting whether the test sample contains cells expressing a mutant Ras having a substitution of a glycine, a lysine, or a glutamine for the glutamate at position 76 with respect to the wild-type Ras amino acid sequence. ### Claim 2 (depends on 1) The method of claim 1, wherein the method further comprises detecting whether the test sample contains cells expressing a mutant Ras having a mutation of the amino acid at position 13 with respect to the wild-type Ras amino acid sequence. ### Claim 3 (depends on 1) The method of claim 1, wherein the method further comprises detecting whether the test sample contains cells expressing a mutant Ras having a mutation of the amino acid at position 12 with respect to the wild-type Ras amino acid sequence. ### Claim 4 (depends on 1) The method of claim 1, wherein the step of detecting comprises detecting a nucleic acid sequence encoding the mutant Ras in nucleic acids in the test sample. ### Claim 5 (depends on 4) The method of claim 4, wherein the step of detecting comprises PCR amplification of nucleic acids in the test sample of genomic DNA encoding Ras or in situ PCR amplification of nucleic acids in the test sample of DNA sequences encoding Ras. ### Claim 6 (depends on 1) The method of claim 1, wherein the step of detecting is performed using a method selected from the group consisting of polymerase chain reaction (PCR), reverse transcriptase-PCR (RT-PCR), in situ hybridization, Northern blot, sequence analysis, gene microarray analysis, and detection of a reporter gene. ### Claim 7 (depends on 1) The method of claim 1, wherein the step of detecting is performed by contacting nucleic acids isolated from the test sample with a primer or probe that selectively binds to a nucleic acid sequence encoding Ras, and detecting whether the primer or probe hybridizes to and/or amplifies the nucleic acid sequence under conditions such that one determines whether the nucleic acid sequence encodes a mutant Ras having a substitution of a glycine, a lysine, or a glutamine for the glutamate at position 76. ### Claim 8 (depends on 1) The method of claim 1, wherein the test sample is a tumor sample. ### Claim 9 (depends on 1) The method of claim 1, wherein the test sample is a blood sample. ### Claim 10 (depends on 1) The method of claim 1, wherein the test sample is from a patient being diagnosed for cancer and wherein the test sample is compared to a negative control sample. ### Claim 11 (depends on 1) The method of claim 1, wherein the test sample is immobilized on a substrate. ### Claim 12 (depends on 1) The method of claim 1, wherein the method is used to diagnose cancer in the patient. ### Claim 13 (depends on 1) The method of claim 1, wherein the method is used to determine the prognosis for cancer in the patient. ### Claim 14 A method for detecting ras having a mutation at codon 76 in a patient tumor sample, comprising: a) isolating genomic DNA from a patient tumor sample; b) amplifying a DNA fragment from the genomic DNA using oligonucleotide PCR primers that flank a ras nucleic acid sequence that includes nucleotides encoding the amino acid at position 76 of Ras; and c) probing the amplified sequence with oligonucleotides that hybridize specifically with sequences containing one or more mutations at codon 76 of ras, but not with wild-type ras sequences, to detect the presence of a nucleic acid sequence encoding Ras having a substitution of a glycine, a lysine, or a glutamine for the glutamate at position 76. ### Claim 15 A method for detecting ras encoding a Ras protein having a mutation of the amino acid at position 76 in a patient tumor sample, comprising: a) obtaining a tumor sample from a patient; and b) performing a hybridization and/or amplification reaction on said tumor sample under conditions such that one determines whether the tumor sample comprises ras encoding a Ras protein having a substitution of a glycine, a lysine, or a glutamine for the glutamate at position 76.